Welcome to LookChem.com Sign In|Join Free
  • or
3-(Trifluoromethyl)cinnamic acid is an organic compound that features a trifluoromethyl group attached to the third carbon of the cinnamic acid backbone. It is a white solid with unique chemical properties that make it suitable for various applications across different industries.

779-89-5

Post Buying Request

779-89-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

779-89-5 Usage

Uses

Used in Pharmaceutical Industry:
3-(Trifluoromethyl)cinnamic acid is used as an intermediate in the synthesis of various pharmaceutical compounds due to its unique trifluoromethyl group, which can enhance the biological activity and pharmacokinetic properties of the resulting drugs.
Used in Chemical Synthesis:
3-(Trifluoromethyl)cinnamic acid serves as a key building block in the preparation of a wide range of chemical products, including agrochemicals, dyes, and specialty chemicals. Its trifluoromethyl group imparts specific reactivity and stability to the synthesized products.
Used in Sedative Hypnotic Applications:
3-(Trifluoromethyl)cinnamic acid has demonstrated sedative hypnotic activity in mice, showing potent inhibition of spontaneous motility. This property makes it a potential candidate for the development of new sedative and hypnotic agents in the pharmaceutical industry.

Check Digit Verification of cas no

The CAS Registry Mumber 779-89-5 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 7,7 and 9 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 779-89:
(5*7)+(4*7)+(3*9)+(2*8)+(1*9)=115
115 % 10 = 5
So 779-89-5 is a valid CAS Registry Number.
InChI:InChI=1/C10H7F3O2/c11-10(12,13)8-3-1-2-7(6-8)4-5-9(14)15/h1-6H,(H,14,15)/p-1/b5-4+

779-89-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-(Trifluoromethyl)cinnamic acid

1.2 Other means of identification

Product number -
Other names 3-rifluoromethyl)CinnamicAcid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:779-89-5 SDS

779-89-5Synthetic route

m-trifluoromethylphenyl iodide
401-81-0

m-trifluoromethylphenyl iodide

acrylic acid methyl ester
292638-85-8

acrylic acid methyl ester

3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

Conditions
ConditionsYield
With triethylamine; di-(3-methylphenyl)phosphinopolystyrene palladium catalyst In acetonitrile at 80℃; for 20h; Heck cross-coupling reaction;96%
malonic acid
141-82-2

malonic acid

3-Trifluoromethylbenzaldehyde
454-89-7

3-Trifluoromethylbenzaldehyde

3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

Conditions
ConditionsYield
With piperidine; pyridine at 110℃;89%
piperidine In pyridine at 110 - 115℃; Knoevenagel-Doebner condensation;72%
With piperidine In pyridine at 80 - 90℃;
m-trifluoromethyl-α-bromohydrocinnamic acid
1015065-52-7

m-trifluoromethyl-α-bromohydrocinnamic acid

3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

Conditions
ConditionsYield
Stage #1: m-trifluoromethyl-α-bromohydrocinnamic acid With sodium hydroxide; water; N-benzyl-N,N,N-triethylammonium chloride In isopropyl alcohol at 55 - 60℃; for 7h;
Stage #2: With hydrogenchloride; water at 0℃;
3-Trifluoromethylbenzaldehyde
454-89-7

3-Trifluoromethylbenzaldehyde

acetic anhydride
108-24-7

acetic anhydride

3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

Conditions
ConditionsYield
at 175℃; for 5.25h;
3-Trifluoromethylbenzaldehyde
454-89-7

3-Trifluoromethylbenzaldehyde

malonic

malonic

3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

Conditions
ConditionsYield
With piperidine; pyridine at 90℃;
(E)-ethyl 3-(3-trifluoromethylphenyl)prop-2-enoate
116577-12-9, 113048-68-3

(E)-ethyl 3-(3-trifluoromethylphenyl)prop-2-enoate

3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

Conditions
ConditionsYield
With lithium hydroxide In tetrahydrofuran; ethanol; water at 20℃; for 4h;
3-Trifluoromethylbenzaldehyde
454-89-7

3-Trifluoromethylbenzaldehyde

3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: dichloromethane / 16 h / 0 - 20 °C
2: lithium hydroxide / tetrahydrofuran; ethanol; water / 4 h / 20 °C
View Scheme
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

trans-3-(trifluoromethyl)cinnamoyl chloride
60689-14-7

trans-3-(trifluoromethyl)cinnamoyl chloride

Conditions
ConditionsYield
With thionyl chloride In dichloromethane; N,N-dimethyl-formamide Reflux; Inert atmosphere;100%
With oxalyl dichloride; calcium carbonate In N,N-dimethyl-formamide; benzene for 24h; Ambient temperature;
With thionyl chloride at 90℃; for 3h;
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

3-(3-trifluoromethylphenyl)propanoic acid
585-50-2

3-(3-trifluoromethylphenyl)propanoic acid

Conditions
ConditionsYield
With hydrogen; palladium dihydroxide at 40 - 60℃; under 2250.23 Torr;100%
With palladium on activated charcoal; hydrogen; sodium carbonate In water at 25℃; under 1500.15 - 2250.23 Torr; for 3h;99.4%
With hydrogen; palladium on activated charcoal In methanol at 20 - 25℃; under 30.003 Torr;95.2%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

N,N-dimethyl-formamide
68-12-2, 33513-42-7

N,N-dimethyl-formamide

(E)-N,N-dimethyl-3-(3-(trifluoromethyl)phenyl)acrylamide
93040-63-2

(E)-N,N-dimethyl-3-(3-(trifluoromethyl)phenyl)acrylamide

Conditions
ConditionsYield
With hydrogenchloride; 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide In 1,4-dioxane at 120℃; for 4h;99%
methanol
67-56-1

methanol

3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

trans-methyl 3-(3-(trifluoromethyl)phenyl)acrylate
104201-66-3

trans-methyl 3-(3-(trifluoromethyl)phenyl)acrylate

Conditions
ConditionsYield
With thionyl chloride at 0℃; for 6h; Inert atmosphere; Reflux;95%
With sulfuric acid Heating;
With sulfuric acid Reflux; Acidic conditions;
With sulfuric acid Inert atmosphere; Reflux;
para-bromotoluene
106-38-7

para-bromotoluene

3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

1-(1-p-tolylvinyl)-3-(trifluoromethyl)benzene

1-(1-p-tolylvinyl)-3-(trifluoromethyl)benzene

Conditions
ConditionsYield
Stage #1: 3-(trifluoromethyl)cinnamic acid With potassium tert-butylate In ethanol at 20℃; for 1h; Inert atmosphere; Sealed tube;
Stage #2: para-bromotoluene With palladium(II) acetylacetonate; 1,10-Phenanthroline; tris-(o-tolyl)phosphine; copper(I) bromide In 1-methyl-pyrrolidin-2-one; quinoline; ethanol at 170℃; for 16h; Heck Reaction; Inert atmosphere; Sealed tube;
94%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

dimethyl sulfate
77-78-1

dimethyl sulfate

trans-methyl 3-(3-(trifluoromethyl)phenyl)acrylate
104201-66-3

trans-methyl 3-(3-(trifluoromethyl)phenyl)acrylate

Conditions
ConditionsYield
With N,N-dimethyl-formamide at 150℃; for 0.333333h;90.9%
With potassium carbonate In acetone Heating;
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

(E)-3-(3-(trifluoromethyl)phenyl)acrylamide
64380-24-1

(E)-3-(3-(trifluoromethyl)phenyl)acrylamide

Conditions
ConditionsYield
Stage #1: 3-(trifluoromethyl)cinnamic acid With thionyl chloride In tetrahydrofuran at 50℃; for 1h;
Stage #2: With ammonium hydroxide In tetrahydrofuran at 0℃; for 0.0833333h;
87%
Multi-step reaction with 2 steps
1: oxalyl chloride, CaCO3 / benzene; dimethylformamide / 24 h / Ambient temperature
2: NH3(gas) / benzene / 12 h
View Scheme
p-cresol
106-44-5

p-cresol

3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

4-(3-(trifluoromethyl)phenyl)-3,4-dihydro-6-methylchromen-2-one

4-(3-(trifluoromethyl)phenyl)-3,4-dihydro-6-methylchromen-2-one

Conditions
ConditionsYield
With sulfuric acid at 110℃; for 12h; Inert atmosphere;85%
With sulfuric acid at 120℃; for 15h;80%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

tartaric acid
87-69-4

tartaric acid

6β-N-methylnaltrexamine
102869-99-8

6β-N-methylnaltrexamine

(2E)-N-[(5R,6R)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-trifluoromethylphenyl)-N-methylprop-2-enamide tartrate

(2E)-N-[(5R,6R)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-trifluoromethylphenyl)-N-methylprop-2-enamide tartrate

Conditions
ConditionsYield
Stage #1: 3-(trifluoromethyl)cinnamic acid; 6β-N-methylnaltrexamine
Stage #2: tartaric acid
84%
3-(2,4,5-trimethoxyphenyl)-(2E)-2-propen-1-ol
1392497-89-0

3-(2,4,5-trimethoxyphenyl)-(2E)-2-propen-1-ol

3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

(E)-3-(2,4,5-trimethoxyphenyl)allyl (E)-3-(3-(trifluoromethyl)phenyl)acrylate

(E)-3-(2,4,5-trimethoxyphenyl)allyl (E)-3-(3-(trifluoromethyl)phenyl)acrylate

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; Inert atmosphere;77.7%
2-(2-(piperazin-1-yl)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione
66235-11-8

2-(2-(piperazin-1-yl)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione

3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

(E)-2-(2-(4-(3-(3-(trifluoromethyl)phenyl)acryloyl)piperazin-1-yl)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione

(E)-2-(2-(4-(3-(3-(trifluoromethyl)phenyl)acryloyl)piperazin-1-yl)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 14h;75%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

glycine tert-butyl ester hydrochloride
27532-96-3

glycine tert-butyl ester hydrochloride

C16H18F3NO3

C16H18F3NO3

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In tetrahydrofuran; N,N-dimethyl-formamide at 20℃;69%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

melampomagnolide B
93930-15-5

melampomagnolide B

((1aR,7aS,10aS,10bS,E)-1a-methyl-8-methylene-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-5-yl)methyl (E)-3-(3-(trifluoromethyl)phenyl)acrylate

((1aR,7aS,10aS,10bS,E)-1a-methyl-8-methylene-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-5-yl)methyl (E)-3-(3-(trifluoromethyl)phenyl)acrylate

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 0 - 20℃; for 8h; Inert atmosphere;69%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

withangulatin A

withangulatin A

C40H43F3O9

C40H43F3O9

Conditions
ConditionsYield
Stage #1: 3-(trifluoromethyl)cinnamic acid With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 0℃; for 1h;
Stage #2: withangulatin A In dichloromethane at 25℃; for 24h;
67%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

sodium benzenesulfonate
873-55-2

sodium benzenesulfonate

(E)-1-(2-((phenyl)sulfonyl)vinyl)-3-trifluoromethylbenzene
1554271-74-7

(E)-1-(2-((phenyl)sulfonyl)vinyl)-3-trifluoromethylbenzene

Conditions
ConditionsYield
With [bis(acetoxy)iodo]benzene In N,N-dimethyl-formamide at 100℃; for 0.166667h;63%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

3-(1-methyl-1H-indol-3-yl)-3-oxopropanenitrile
343778-74-5

3-(1-methyl-1H-indol-3-yl)-3-oxopropanenitrile

2-(1-methyl-1H-indol-3-yl)-5-(3-(trifluoromethyl)phenyl)furan-3-carbonitrile

2-(1-methyl-1H-indol-3-yl)-5-(3-(trifluoromethyl)phenyl)furan-3-carbonitrile

Conditions
ConditionsYield
With di-tert-butyl peroxide; copper diacetate In dimethyl sulfoxide at 90℃; for 8h; Sealed tube; Inert atmosphere; regioselective reaction;61%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

2-amino-benzenethiol
137-07-5

2-amino-benzenethiol

2,3-dihydro-2-(3-trifluoromethylphenyl)-1,5-benzothiazepin-4(5H)-one

2,3-dihydro-2-(3-trifluoromethylphenyl)-1,5-benzothiazepin-4(5H)-one

Conditions
ConditionsYield
With tetrabutyl ammonium fluoride In neat (no solvent) at 80℃; for 24h; Green chemistry;57%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

methyllithium
917-54-4

methyllithium

(E)-4-(3-trifluoromethylphenyl)but-3-en-2-one
84175-48-4

(E)-4-(3-trifluoromethylphenyl)but-3-en-2-one

Conditions
ConditionsYield
In diethyl ether at 5 - 20℃; for 22h;54%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

A

(Z)-β-bromo-3-trifluoromethylstyrene
114092-60-3

(Z)-β-bromo-3-trifluoromethylstyrene

B

(E)-1-(2-bromovinyl)-3-trifluoromethylbenzene
114092-59-0

(E)-1-(2-bromovinyl)-3-trifluoromethylbenzene

Conditions
ConditionsYield
With N-Bromosuccinimide; lithium acetate In acetonitrile for 0.0333333h; microwave irradiation;A n/a
B 52%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-(3-trifluoromethyl-phenyl)-acrylamide

trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-(3-trifluoromethyl-phenyl)-acrylamide

Conditions
ConditionsYield
52%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

4-phenyl-2-(2-phenylthiazol-4-yl)oxazole

4-phenyl-2-(2-phenylthiazol-4-yl)oxazole

2-phenyl-4-(6-phenyl-3-(3-(trifluoromethyl)phenyl)pyridin-2-yl)thiazole

2-phenyl-4-(6-phenyl-3-(3-(trifluoromethyl)phenyl)pyridin-2-yl)thiazole

Conditions
ConditionsYield
In 1,2-dichloro-benzene at 180℃; for 24h; Sealed tube; Inert atmosphere;51%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

ammonium thiocyanate
1147550-11-5

ammonium thiocyanate

(E)-1-(2-thiocyanatovinyl)-3-(trifluoromethyl)benzene

(E)-1-(2-thiocyanatovinyl)-3-(trifluoromethyl)benzene

Conditions
ConditionsYield
With ammonium acetate; sodium perchlorate; sodium hydrogencarbonate In water; acetonitrile at 20℃; for 9h; Electrolysis; Green chemistry;51%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

Langlois reagent
2926-29-6

Langlois reagent

1-[(E)-3,3,3-trifluoro-1-propen-1-yl]-3-trifluoromethylbenzene
78622-59-0

1-[(E)-3,3,3-trifluoro-1-propen-1-yl]-3-trifluoromethylbenzene

Conditions
ConditionsYield
With 2,2,2-trifluoroethanol; lithium perchlorate In 1,2-dimethoxyethane; water at 20℃; for 12h; Electrochemical reaction; Green chemistry; stereoselective reaction;51%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

(Z)-N'-hydroxybutyrimidamide
27620-10-6

(Z)-N'-hydroxybutyrimidamide

(E)-3-propyl-5-(3-(trifluoromethyl) styryl)-1,2,4-oxadiazole

(E)-3-propyl-5-(3-(trifluoromethyl) styryl)-1,2,4-oxadiazole

Conditions
ConditionsYield
Stage #1: 3-(trifluoromethyl)cinnamic acid With 1,1'-carbonyldiimidazole In toluene at 20℃;
Stage #2: (Z)-N'-hydroxybutyrimidamide In toluene at 20 - 110℃;
48.5%
meta-fluoroaniline
372-19-0

meta-fluoroaniline

3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

(E)-3-(3-(trifluoromethyl)phenyl)-N-(3-fluorophenyl)-2-propenamide

(E)-3-(3-(trifluoromethyl)phenyl)-N-(3-fluorophenyl)-2-propenamide

Conditions
ConditionsYield
Stage #1: 3-(trifluoromethyl)cinnamic acid With 4-methyl-morpholine; isobutyl chloroformate In tetrahydrofuran at -78℃; for 0.116667h;
Stage #2: meta-fluoroaniline In tetrahydrofuran at -78 - 20℃;
43%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

5-chloro-2-(4-methoxyphenyl)-4-phenyloxazole

5-chloro-2-(4-methoxyphenyl)-4-phenyloxazole

A

6-(4-methoxyphenyl)-2-phenyl-5-(3-(trifluoromethyl)phenyl)pyridin-3-ol

6-(4-methoxyphenyl)-2-phenyl-5-(3-(trifluoromethyl)phenyl)pyridin-3-ol

B

6-(4-methoxyphenyl)-2-phenyl-4-(3-(trifluoromethyl)phenyl)pyridin-3-ol

6-(4-methoxyphenyl)-2-phenyl-4-(3-(trifluoromethyl)phenyl)pyridin-3-ol

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine at 180℃; for 24h; Reagent/catalyst; Sealed tube; Inert atmosphere;A 43%
B 17%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

N1-(1,2,3,4-tetrahydroacridin-9-yl)hexane-1,6-diamine
249290-17-3

N1-(1,2,3,4-tetrahydroacridin-9-yl)hexane-1,6-diamine

(E)-N-(6-((1,2,3,4-tetrahydroacridin-9-yl)amino)hexyl)-3-(3-(trifluoromethyl)phenyl)acrylamide

(E)-N-(6-((1,2,3,4-tetrahydroacridin-9-yl)amino)hexyl)-3-(3-(trifluoromethyl)phenyl)acrylamide

Conditions
ConditionsYield
With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 24h;38%
3-(trifluoromethyl)cinnamic acid
779-89-5

3-(trifluoromethyl)cinnamic acid

pinacol benzylboronate
87100-28-5

pinacol benzylboronate

C16H13F3

C16H13F3

Conditions
ConditionsYield
With silver carbonate; copper(II) oxide In dimethyl sulfoxide at 120℃; for 12h; Inert atmosphere;38%

779-89-5Relevant academic research and scientific papers

Design, Synthesis, and Anticancer Activity of Cinnamoylated Barbituric Acid Derivatives

Li, Peng-Xiao,Liu, Guo-Yun,Liu, Ren-Min,Liu, Yue,Mu, Wen-Wen,Sun, Ya-Lei,Yang, Jie

, (2022/01/13)

This work deals with the design and synthesis of 18 barbituric acid derivatives bearing 1,3-dimethylbarbituric acid and cinnamic acid scaffolds to find potent anticancer agents. The target molecules were obtained through Knoevenagel condensation and acylation reaction. The cytotoxicity was assessed by the MTT assay. Flowcytometry was performed to determine the cell cycle arrest, apoptosis, ROS levels and the loss of MMP. The ratios of GSH/GSSG and the MDA levels were determined by using UV spectrophotometry. The results revealed that introducing substitutions (CF3, OCF3, F) on the meta- of the benzyl ring of barbituric acid derivatives led to a considerable increase in the antiproliferative activities compared with that of corresponding ortho- and para-substituted barbituric acid derivatives. Mechanism investigation implied that the 1c could increase the ROS and MDA level, decrease the ratio of GSH/GSSG and MMP, and lead to cell cycle arrest. Further research is needed for structural optimization to enhance hydrophilicity, thereby improve the biological activity of these compounds.

Phenanthroline functionalized polyacrylonitrile fiber with Pd(0) nanoparticles as a highly active catalyst for the Heck reaction

Xiao, Jian,Zhang, Haonan,Ejike, Anyaegbu Chima,Wang, Lu,Tao, Minli,Zhang, Wenqin

, (2021/03/03)

A series of polyacrylonitrile fibers (PANF) functionalized with nitrogen-containing ligands were prepared and then used to synthesize fiber-supported Pd(0) nanoparticle catalysts. The phenanthroline-functionalized PANF with immobilized Pd(0) nanoparticles (PANPhenF-Pd(0)) had the best catalytic activity for the Heck reaction under solvent-free conditions. The PANPhenF-Pd(0) efficiently stabilized the nanoparticles and they were well-dispersed with Pd(0) particle sizes of about 3 nm. The PANPhenF-Pd(0) structure was further characterized by a variety of instrumental methods. A probable mechanism based on the fiber's microenvironment is proposed for the Heck reaction catalyzed by PANPhenF-Pd(0). The PANPhenF-Pd(0) catalyst is easily recovered from the reaction system and can be used up to six times with only a slight decrease in catalytic activity and with low Pd leaching. The PANPhenF-Pd(0) catalyst also has excellent catalytic activity for gram-scale use.

Piperlongumine analogs promote A549 cell apoptosis through enhancing ROS generation

Li, Peng-Xiao,Li, Yan-Mo,Liu, Guo-Yun,Liu, Ren-Min,Mu, Wen-Wen,Sun, Ai-Ling,Sun, Ya-Lei,Yang, Jie

, (2021/06/11)

Chemotherapeutic agents, which contain the Michael acceptor, are potent anticancer molecules by promoting intracellular reactive oxygen species (ROS) generation. In this study, we synthesized a panel of PL (piperlongumine) analogs with chlorine attaching at C2 and an electronwithdrawing/electron-donating group attaching to the aromatic ring. The results displayed that the strong electrophilicity group at the C2–C3 double bond of PL analogs plays an important role in the cytotoxicity whereas the electric effect of substituents, which attached to the aromatic ring, partly contributed to the anticancer activity. Moreover, the protein containing sulfydryl or seleno, such as TrxR, could be irreversibly inhibited by the C2–C3 double bond of PL analogs, and boost intracellular ROS generation. Then, the ROS accumulation could disrupt the redox balance, induce lipid peroxidation, lead to the loss of MMP (Mitochondrial Membrane Potential), and ultimately result in cell cycle arrest and A549 cell line death. In conclusion, PL analogs could induce in vitro cancer apoptosis through the inhibition of TrxR and ROS accumulation.

Discovery of 3-cinnamamido-n-substituted benzamides as potential antimalarial agents

Futamura, Yushi,Ishiyama, Aki,Iwatsuki, Masato,Liu, Haicheng,Osada, Hiroyuki,Shi, Tao,Wu, Honghai,Zhang, Taotao,Zheng, Qunxiong,Zou, Hongbin,ōmura, Satoshi

, p. 1207 - 1218 (2022/01/06)

Background: Malaria is one of the most devastating parasitic diseases, yet the discovery of antimalarial agents remains profoundly challenging. Very few new antimalarials have been developed in the past 50 years, while the emergence of drug-resistance continues to appear. Objective: This study focuses on the discovery, design, synthesis, and antimalarial evaluation of 3- cinnamamido-N-substituted benzamides. Methods: In this study, a screening of our compound library was carried out against the multidrugsensitive Plasmodium falciparum 3D7 strain. Derivatives of the hit were designed, synthesized and tested against P. falciparum 3D7 and the in vivo antimalarial activity of the most active compounds was evaluated using the method of Peters’ 4-day suppressive test. Results: The retrieved hit compound 1 containing a 3-cinnamamido-N-substituted benzamide skeleton showed moderate antimalarial activity (IC50 = 1.20 μM) for the first time. A series of derivatives were then synthesized through a simple four-step workflow, and half of them exhibited slightly better antimalarial effect than the precursor 1 during the subsequent in vitro assays. Additionally, compounds 11, 23, 30 and 31 displayed potent activity with IC50 values of approximately 0.1 μM, and weak cytotoxicity against mammalian cells. However, in vivo antimalarial activity is not effective, which might be ascribed to the poor solubility of these compounds. Conclusion: In this study, the phenotypic screen of our compound library resulted in the first report of a 3-cinnamamide framework with antimalarial activity and 40 derivatives were then designed and synthesized. Subsequent structure-activity studies showed that compounds 11, 23, 30 and 31 exhibited the most potent and selective activity against the P. falciparum 3D7 strain with IC50 values around 0.1 μM. Our work herein sets another example of phenotypic screen-based drug discovery, leading to potentially promising candidates of novel antimalarial agents once given further optimization.

Dual Nickel/Ruthenium Strategy for Photoinduced Decarboxylative Cross-Coupling of α,β-Unsaturated Carboxylic Acids with Cycloketone Oxime Esters

Gao, Ang,Jiang, Run-Chuang,Liu, Chuang-Chuang,Liu, Qi-Le,Lu, Xiao-Yu,Xia, Ze-Jie

supporting information, p. 8829 - 8842 (2021/06/30)

Herein, a dual nickel/ruthenium strategy is developed for photoinduced decarboxylative cross-coupling between α,β-unsaturated carboxylic acids and cycloketone oxime esters. The reaction mechanism is distinct from previous photoinduced decarboxylation of α,β-unsaturated carboxylic acids. This reaction might proceed through a nickelacyclopropane intermediate. The C(sp2)-C(sp3) bond constructed by the aforementioned reaction provides an efficient approach to obtaining various cyanoalkyl alkenes, which are synthetically valuable organic skeletons in organic and medicinal chemistry, under mild reaction conditions. The protocol tolerates many critical functional groups and provides a route for the modification of complex organic molecules.

Metal-Free Hydropyridylation of Thioester-Activated Alkenes via Electroreductive Radical Coupling

Xu, Hehuan,Liu, Jiayu,Nie, Feiyun,Zhao, Xiaowei,Jiang, Zhiyong

, p. 16204 - 16212 (2021/10/25)

An electrochemical hydropyridylation of thioester-activated alkenes with 4-cyanopyridines has been developed. The reactions experience a tandem electroreduction of both substrates on the cathode surface, protonation, and radical cross-coupling process, resulting in a variety of valuable pyridine variants, which contain a tertiary and even a quaternary carbon at the α-position of pyridines, in high yields. The employment of thioesters to the conjugated alkenes enables no requirement of catalyst and high temperature, representing a highly sustainable synthetic method.

Meta-substituted piperlongumine derivatives attenuate inflammation in both RAW264.7 macrophages and a mouse model of colitis

Gong, Zhaotang,Liu, Guoyun,Mu, Wenwen,Wang, Ziqing,Yang, Jie

, (2021/11/16)

Piperlongumine (PL) has been showed to have multiple pharmacological activities. In this study, we reported the synthesis of three series of PL derivatives, and evaluation of their anti-inflammatory effects in both lipopolysaccharide (LPS)-induced Raw264.7 macrophages and a dextran sulfate sodium (DSS)-induced mouse model of colitis. Our results presented that two meta-substituent containing derivatives 1–3 and 1–6, in which γ-butyrolactam replaced α,β-unsaturated δ-valerolactam ring of PL, displayed low cytotoxicity and effective anti-inflammatory activity. Molecular docking also showed that the meta-substituted derivative, compared with the corresponding ortho- or para-substituted derivative, had significant interactions with the amino acid residues of CD14, which was the core receptors recognizing LPS. In vitro and in vivo studies, 1–3 and 1–6 could inhibit the expression of pro-inflammatory cytokines, and the excessive production of reactive nitrogen species and reactive oxygen species. Oral administration of 100 mg/kg/day of 1–3 or 1–6 alleviated the severity of clinical symptoms of colitis in mice, and significantly reduced the colonic tissue damage to protect the colonic tissue from the DSS-induced colitis. These results suggested that meta-substituted derivatives 1–3 and 1–6 were potential anti-inflammatory agents, which may lead to future pharmaceutical development.

The potential role of the 5,6-dihydropyridin-2(1: H)-one unit of piperlongumine on the anticancer activity

Li, Peng-Xiao,Liu, Guo-Yun,Liu, Yue,Mu, Wen-Wen,Yang, Jie

, p. 42128 - 42136 (2020/12/09)

Piperlongumine (PL), a potent anticancer agent from the plant long pepper (Piper longum), contains the 5,6-dihydropyridin-2(1H)-one heterocyclic scaffold and cinnamoyl unit. In this paper, we synthesized a series of PL analogs and evaluated their cytotoxicity against cancer cells for the sake of exploring which pharmacophore plays a more potent role in enhancing the anticancer activities of PL. These results illustrated that the position effect, not the electronic effect, of substituents plays a certain role in the cytotoxicity of PL and its analogs. More important, the 5,6-dihydropyridin-2(1H)-one unit, a potent pharmacophore in enhancing the antiproliferative activities of PL, could react with cysteamine and lead to ROS generation, and then bring about the occurrence of ROS-induced downstream events, followed by cell cycle arrest and apoptosis. This work suggests that introducing a lactam unit containing Michael acceptors may be a potent strategy to enhancing the anticancer activity of drugs. This journal is

New coumarin/sulfocoumarin linked phenylacrylamides as selective transmembrane carbonic anhydrase inhibitors: Synthesis and in-vitro biological evaluation

Angeli, Andrea,Arifuddin, Mohammed,Singh, Priti,Supuran, Claudiu T.,Swain, Baijayantimala

, (2020/07/03)

Two novel series of phenylacrylamide linked coumarins and sulfocoumarins (6a-p, 8a-i, and 14a-g) were synthesized and evaluated against four physiologically relevant human carbonic anhydrases (hCAs, EC 4.2.1.1), isoforms hCA I, hCA II, hCA IX and hCA XII for their inhibitory action. All new compounds when screened for carbonic anhydrase inhibitory activity have shown selective inhibition towards the tumor associated isoforms hCA IX and XII over CA I and II, with inhibition constants in the submicromolar to low nanomolar range. Compound 6b and 14g exhibited significant inhibition with low nanomolar potency against hCA IX, whereas 6k was effective against hCA XII. Compounds 6b, 14g and 6k may be considered as lead molecules for future development of cancer therapeutics based on a novel mechanism of action.

Design, synthesis and biological evaluation of (E)-5-styryl-1,2,4-oxadiazoles as anti-tubercular agents

Atmaram Upare, Abhay,Gadekar, Pradip K.,Sivaramakrishnan,Naik, Nishigandha,Khedkar, Vijay M.,Sarkar, Dhiman,Choudhari, Amit,Mohana Roopan

supporting information, p. 507 - 512 (2019/02/19)

Cinnamic acid and its derivatives are known for anti-tubercular activity. The present study reports the synthesis of cinnamic acid derivatives via bioisosteric replacement of terminal carboxylic acid with “oxadiazole”. A series of cinnamic acid derivatives (styryl oxadiazoles) were designed and synthesized in good yields by reaction of substituted cinnamic acids (2, 15a-15s) with amidoximes. The synthesized styryl oxadiazoles were evaluated in vitro for anti-tubercular activity against Mycobacterium tuberculosis (Mtb) H37Ra strain. The structure-activity relationship (SAR) study has identified several compounds with mixed anti-tubercular profiles. The compound 32 displayed potent anti-tubercular activity (IC50 = 0.045 μg/mL). Molecular docking studies on mycobacterial enoyl-ACP reductase enzyme corroborated well with the experimental findings providing a platform for structure based hit-to-lead development.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 779-89-5